… encouraging results of targeted therapy in patients with EGFR-mutant and ALK-rearranged …
are being made to develop and integrate targeted agents in clinical practice for NSCLC. Here…

… Personalized therapy encompasses the strategy of matching these subtypes with
effective targeted therapies. EGFR mutations and ALK translocation are the most effectively …

… Here, we review the clinical trials of novel therapies and combination regimens … to targeted
therapy. The aim of these trials was to enhance the therapeutic efficacy of targeted therapies …

… phosphorylation of ALK and EGFR in concomitant EGFR/ALK mutations NSCLC … target
therapies. In (A) higher level of phosphorylation of ALK than EGFR, with better response to EGFR-…

… of molecularly targeted therapies. These include monoclonal antibodies targeting specific
… factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements (…

… , EGFR and ALK … targeted therapy as the standard of care in each respective patient
population. On the basis of the success of targeted therapies in patients with EGFR-mutant and ALK-…

… ALK rearrangements, the clinical epidemiology of lung cancer driven by ALK, the clinical data
for ALK-targeted therapy … response to EGFR TKI would be strongly helpful in ALK screening…

… EGFR-mutant and ALK-rearranged NSCLC have informed the paradigm of targeted therapy
… an overview of the development of EGFR and ALK targeted therapies with a focus on third-…

… We conducted a phase Ib trial to examine the safety of concurrent ipilimumab combined
with targeted therapy in ALK-rearranged or EGFR-mutated advanced NSCLC. …

… targeting EGFR family members, novel EML4-ALK inhibitors and MEK inhibitors are currently
in clinical development. Availability of targeted therapies … in use of targeted therapy, with a …